PharmaTelevision - Psioxus CEO John Beadle talks about their cachexia program

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Psioxus CEO John Beadle talks about their cachexia program

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to John Beadle, CEO of Psioxus.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

PsiOxus Therapeutics: Origin and focus

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington. On this show I have John Beadle, who is CEO of a company called PsiOxus Therapeutics based in Oxford, welcome.

John Beadle:

Thank you, good morning.

Fintan Walton:

Good morning to you. John, PsiOxus could you tell us what that company is you are obviously CEO of that company and how it emerged as a biotech company and what it focuses on?

John Beadle:

Certainly, we are an oncology focused biotechnology company, we are based in Oxford in the UK and we were created in December of 2010 from the merger of two different spin-out companies Myotec which was from Imperial College London and then Hybrid BioSystems which was out of Oxford University.

Fintan Walton:

And by bringing those two companies together what were you bringing together?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

John Beadle

CEO

John Beadle was Entrepreneur in Residence at Imperial College, where he helped to establish Myotec Therapeutics Ltd as a spinout business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a "5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems Ltd , securing further seed financing for this Oxford based start-up. In 2010, John's leadership of these two private companies led to their combination to form PsiOxus Therapeutics. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise "20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

PsiOxus Therapeutics

PsiOxus Therapeutics was formed in 2010 through the combination of Myotec Therapeutics Ltd and Hybrid Biosystems Ltd . Myotec was formed in 2006 as an Imperial College spin out company based upon the world leading research of Professor Stefan Anker and Professor Andrew Coats into the underlying mechanisms of cachexia across a wide range of chronic disease states. Myotec identified and developed the lead program, MT-102, to the point of phase II clinical development. MT-102 has a unique combination of pharmacological effects to produce a Anabolic Catabolic Transforming Agent (ACTA) with an excellent pre-clinical efficacy profile, as demonstrated in animal models of cachexia and sarcopenia . MT-102 has been dosed to 132 patients in two clinical studies and has a very good human safety profile. MT-102 and our follow-on programs are being developed in close collaboration with Professor Anker's specialist cachexia research group at the Charite Medical School in Berlin. Hybrid based upon the groundbreaking research of Professor Len Seymour and Dr Kerry Fisher. Hybrid's early research was into the use of viruses as a unique form of therapeutics. ColoAd1 was developed in collaboration with Berlex (now Bayer Schering) as a unique chimeric oncolytic virus. Hybrid's scientists also developed the stealthed vaccine vector system called PolySTAR, which is a polymer coated recombinant viral vector and the potent adjuvant and immunotherapeutic system called PolyMAP.